tbuckley/cabot-search huggingface dataset:
Genetic Basis for Congenital Heart Disease: Revisited: A Scientific Statement From the American Heart Association
Authors: Mary Ella Pierpont, Martina Brueckner, Wendy K. Chung, Vidu Garg, Ronald V. Lacro, Amy L. McGuire, Seema Mital, James R. Priest, William T. Pu, Amy Roberts, Stephanie M. Ware, Bruce D. Gelb, Mark W. Russell
Journal: Circulation (2018)

This review provides an updated summary of the state of our knowledge of the genetic contributions to the pathogenesis of congenital heart disease. Since 2007, when the initial American Heart Association scientific statement on the genetic basis of congenital heart disease was published, new genomic techniques have become widely available that have dramatically changed our understanding of the causes of congenital heart disease and, clinically, have allowed more accurate definition of the pathogeneses of congenital heart disease in patients of all ages and even prenatally. Information is presented on new molecular testing techniques and their application to congenital heart disease, both isolated and associated with other congenital anomalies or syndromes. Recent advances in the understanding of copy number variants, syndromes, RASopathies, and heterotaxy/ciliopathies are provided. Insights into new research with congenital heart disease models, including genetically manipulated animals such as mice, chicks, and zebrafish, as well as human induced pluripotent stem cell-based approaches are provided to allow an understanding of how future research breakthroughs for congenital heart disease are likely to happen. It is anticipated that this review will provide a large range of health care-related personnel, including pediatric cardiologists, pediatricians, adult cardiologists, thoracic surgeons, obstetricians, geneticists, genetic counselors, and other related clinicians, timely information on the genetic aspects of congenital heart disease. The objective is to provide a comprehensive basis for interdisciplinary care for those with congenital heart disease.
MEK5 promotes lung adenocarcinoma
Authors: Adrián Sánchez-Fdez, María Jesús Ortiz-Ruiz, María Florencia Re-Louhau, Isabel Ramos, Óscar Blanco-Múñez, Dolores Ludeña, Mar Abad, Manuel Sánchez-Martín, Atanasio Pandiella, Azucena Esparís-Ogando
Journal: European Respiratory Journal (2018)

Lung cancer represents the leading cause of cancer death worldwide [1]. Because of that, intense efforts are being devoted to the development of novel therapeutic strategies to fight the disease [2]. In this respect, identification of new oncogenic drivers offers therapeutic opportunities in tumours in which those molecules or other cooperating elements play a pathophysiological role. Here, we show that the MEK5 mitogen-activated protein kinase kinase has a pivotal role in lung cancer. MEK5 acts as an oncogenic driver in mice lung cancer and is pivotal for human lung adenocarcinoma <http://ow.ly/M9e830mZb8N> We are grateful to M. Buschbeck (IJC, Barcelona, Spain), P. Lazo (IBMCC, Salamanca, Spain) and J. Losada (IBMCC, Salamanca, Spain) for providing us with the pCDNA3-MEK5, the pCEFL mammalian expression vector and the pMSG vector, respectively. We also thank R. Gervás Ríos and E. Alonso Morrondo (Pathology Service, University Hospital, Salamanca, Spain) for technical assistance in the immunohistochemical analyses.
Keep at Bay
Authors: Eva M. Mathews
Journal: Annals of Internal Medicine (2018)

Ad Libitum20 November 2018Keep at BayEva M. Mathews, MD, MPHEva M. Mathews, MD, MPHLouisiana State University—Our Lady of the Lake, Baton Rouge, Louisiana. (E.M.M.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M18-1066 Audio Reading - “Keep at Bay” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "Keep at Bay," by E.M. Mathews. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail four men ... Author, Article, and Disclosure InformationAffiliations: Louisiana State University—Our Lady of the Lake, Baton Rouge, Louisiana. (E.M.M.)Current Author Address: Eva M. Mathews, MD, MPH; e-mail, Eva.[email protected]org. PreviousarticleNextarticle Advertisement Audio Reading - “Keep at Bay” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "Keep at Bay," by E.M. Mathews. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics 20 November 2018Volume 169, Issue 10Page: 731KeywordsNursesSleep ePublished: 20 November 2018 Issue Published: 20 November 2018 Copyright & PermissionsCopyright © 2018 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Oncostatic effects of melatonin on MCF-7 (ER+) and MDA-MB-231 (ER-) breast cancer cells
Authors: Suresh R. Volate, Ala Y. Issa, Stephanie J. Muga, Michael J. Wargovich
Journal: Cancer Research (2005)

6085  Breast Cancer is the most common cancer among women in the United States and contributes to over 40,000 deaths in 2004. Low levels of circulating melatonin, the major secretory product of the pineal gland, as well as desynchronization of the circadian secretory patterns have been found in patients suffering from breast tumors, suggesting a relationship between pineal function and the carcinogenic process in breast. Consistent with this notion, in vivo studies using the murine mammary tumor model such as 7,12-dimethylbenz[a]anthracene (DMBA) and nitrosomethylurea (NMU) show that administration of melatonin reduced the incidence of mammary tumors. Likewise, direct actions of melatonin on mammary cancer cells are strongly supported by in vitro experiments in which the anti-proliferative as well as the anti-invasive effects of this indoleamine have been demonstrated in ER+ human breast cancer cells (MCF-7). Although these studies suggest a therapeutic value of melatonin on mammary cancer, the effect of melatonin in ER- breast cancer and the mechanism by which it reduces the development of mammary tumors are still unknown; hence, the aim of this project is to investigate whether pharmacological (1 μM) and physiological concentrations (1nM (night peak levels) and 10pM (daytime levels)) of melatonin inhibit cell proliferation in both ER+ (MCF-7) and ER- (MDA-MB-231) breast cancer cell lines and to elucidate the mechanism through which melatonin elicits its response. MCF-7 cells continuously exposed to pharmacological concentrations of melatonin (1μM) or periodically exposed (1μM /10pM alternating every 12 hours), had no effect on proliferation as measured by MTS assay. Conversely, continuous and periodic exposure of melatonin at pharmacological concentrations to MDA-MB-231 cells lead to a 20% decrease in cell growth after 48 hours. Continuous exposure of melatonin at physiological concentration levels (1nM and10pM) lead to a 10% decrease in cell proliferation after 72 hours in both cell lines; this effect was potentiated with time in the MCF-7 cells (35% inhibition after 96 hours), but remained constant in MDA-MB-231 cell line. Western blot analysis of cyclin D1 and cyclin E, proteins which regulate the G1 phase of cell cycle, isolated from cells treated with melatonin at physiological concentrations for 84 hours revealed that melatonin markedly inhibited expression of these proteins as compared to untreated cells. These results indicate that melatonin modulates cell proliferation in both ER+ and ER- breast cancer cell lines thereby suggesting that melatonin retard cells in the G1 phase of the cell cycle. The apoptotic and anti-inflammatory effects of melatonin are being investigated in these cell lines.
Notice of Retraction and Replacement: Roscher et al. Validating 4 Staging Systems for Cutaneous Squamous Cell Carcinoma Using Population-Based Data: A Nested Case-Control Study. <i>JAMA Dermatol</i>. 2018;154(4):428-434.
Authors: Ingrid Roscher, Ragnhild S. Falk, Linda Vos, Ole P. F. Clausen, Per Helsing, Petter Gjersvik, Trude E. Robsahm
Journal: JAMA Dermatology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
CNS inflammatory disorder after concurrent radiotherapy-temozolomide and nivolumab in a glioblastoma patient
Authors: Anna Luisa Di Stefano, Julien Savatovsky, Loic Feuvret, Chiara Villa, Vincent Reina, Micheline Pha, Caroline Houillier, Giulia Berzero, Ahmed Idbaih, Dimitri Psimaras
Journal: Neuro-Oncology (2018)
A Sequential Cohort Study of Pathogen Reduced Platelet Component Transfusion without Use of Leukocyte Reduction for Hematopoietic Stem Cell Transplant (HSCT): Impact on Clinical Refractoriness
Authors: Laurence Corash, Joycelyn Sim, Wai-Chiu Tsoi, Cheuk Kwong Lee, Rock Y.Y. Leung, Yingjie Liu, Norman Huang, Clarence C.K. Lam, Hans Vermeij, Adonis Stassinopoulos, Richard J. Benjamin, Albert Kwok Wai Lie
Journal: Blood (2018)
Combination treatment of acute myeloid leukemia cells with DNMT and HDAC inhibitors: predominant synergistic gene downregulation associated with gene body demethylation
Authors: Nadja Blagitko-Dorfs, Pascal Schlosser, Gabriele Greve, Dietmar Pfeifer, Ruth Meier, Annika Baude, David Brocks, Christoph Plass, Michael Lübbert
Journal: Leukemia (2018)
Association of fruit and vegetable consumption with endometrial cancer risk
Authors: Menghua Tao, Wanghong Xu, Wei Zheng, Yu Tang Gao, Zhi Xian Ruan, Jia Rong Cheng, Yong Bing Xiang, Xiao Ou Shu
Journal: Cancer Research (2005)

5824  Abstract: Objectives: To evaluate associations of fruits and vegetables consumptions with endometrial cancer risk in a population-based case-control study among Chinese women in Shanghai. Methods: This study included 832 incident endometrial cancer cases and 846 frequency-matched controls. Usual dietary habits were estimated by in-person interviews through a validated, quantative, food-frequency questionnaire. Logistic regression was used to estimate adjusted odds ratios (OR) and their 95% confidence intervals (95% CI) of endometrial cancer. Results: There was an inverse relationship between consumption of total vegetables and endometrial cancer risk (highest quartile vs lowest: OR=0.69, 95% CI 0.50-0.96). The risk of endometrial cancer was reduced with increasing intake of dark green/ dark yellow vegetables (trend test, p=0.02), fresh legumes (trend test, p
Abstract 20929: Impact of Complete Revascularization on Long-Term Clinical Outcomes in Patients With Multi-Vessel Disease Including Chronic Total Occlusion
Authors: Ji Bak Kim, Byoung Geol Choi, Seung-Woon Rha, Ho-Jun Jang, Rak-Kyeong Choi, Young Jin Choi, Dong Joo Oh
Journal: Circulation (2017)

Introduction: Chronic total occlusion (CTO) intervention is still challenging because of the limited procedural success rate and higher recurrence. Also, it is not clear whether the complete revascularization will significantly improve the angiographic and clinical outcomes in patients with multi-vessel disease (MVD) including CTO. Hypothesis: We assessed that the impact of complete revascularization on long-term clinical outcomes in patients with MVD including CTO. Methods: A total of 559 CTO patients with MVD who underwent percutaneous coronary intervention (PCI) for CTO lesion at Sejong General Hospital and Korea University Guro Hospital were enrolled and divided into two groups according to complete revascularization (CTO-PCI; n=325) or not (optimal medial therapy for non-CTO lesion, CTO-OMT; n=234). To adjust potential confounders, a propensity score matching (PSM) analysis was performed. The individual and composite major clinical outcomes were compared between the two groups up to 5 years. Results: After PSM analysis, two PSM groups (186 pairs, total=372) were generated and the baseline characteristics were balanced. Although the CTO-PCI group showed a higher incidence of target lesion and vessel revascularization (TLR and TVR) on CTO, there was a trend toward lower incidence of myocardial infarction (MI) and the incidence of total death or myocardial infarction (MI) was lower in the CTO-PCI group compared with the CTO-OMT group up to 5 years (Table). Conclusions: In the present study, successful CTO-PCI was associated with a lower trend of MI as well as reduction of the risk of total death or MI up to 5-year in CTO patients with MVD regardless of treatment strategy for the non-CTO target vessel.
Acquired mechanisms of immune escape in cancer following immunotherapy
Authors: J. Bryan Iorgulescu, David Braun, Giacomo Oliveira, Derin B. Keskin, Catherine J. Wu
Journal: Genome Medicine (2018)

Immunotherapy has revolutionized the management of numerous cancers; however, a substantial proportion that initially respond subsequently acquire means of immune escape and relapse. Analysis of recent clinical trials permits us to preliminarily understand how immunotherapies exert evolutionary pressures: selecting cancer subclones deficient in antigenicity and/or immunogenicity, thereby facilitating immune escape.
Melanomas of the head and neck have high–local recurrence risk features and require tissue-rearranging reconstruction more commonly than basal cell carcinoma and squamous cell carcinoma: A comparison of indications for microscopic margin control prior to reconstruction in 13,664 tumors
Authors: William Fix, Jeremy R. Etzkorn, Thuzar M. Shin, Nicole Howe, Mehul Bhatt, Joseph F. Sobanko, Christopher J. Miller
Journal: Journal of the American Academy of Dermatology (2018)
The growing problem of diabetes
Authors: Fiona Godlee
Journal: BMJ (2018)

Type 2 diabetes affects nearly 10% of the world’s adults, and rates are rising rapidly, especially in low and middle income countries.1 In the UK it affects about four million adults (6% of the population), and if nothing changes this will grow to about five million by 2025.2 And new figures released this week by Diabetes UK show that in England and Wales nearly 7000 people under age 25 now have type 2 diabetes (doi:10.1136/bmj.k4929).

With such numbers, diabetes in one form …
Abstract MP04: Sex Hormones and 10 Year Progression of Coronary Artery Calcium Among Post-Menopausal Women in the Multi-Ethnic Study of Atherosclerosis
Authors: Vinita Subramanya, Di Zhao, Pamela Ouyang, Wendy Ying, Dhananjay Vaidya, Eliseo Guallar, Chiadi E Ndumele, Susan R Heckbert, Matthew J Budoff, Wendy S Post, Erin D Michos
Journal: Circulation (2018)

Background: Cardiovascular disease (CVD) is the leading cause of death in women. Sex differences in risk factors, prevalence and mortality suggest the involvement of sex hormones in disease processes. Coronary artery calcium (CAC) is a marker of subclinical atherosclerosis and its progression. CAC is prognostic of CVD risk, independent of traditional risk factors, even among low-risk women. We hypothesized that a more androgenic hormone pattern will predict CAC progression over 10 years in post-menopausal women. Methods: We studied 2759 post-menopausal women, aged 45-84 years, participating in MESA who underwent serum sex hormone measurement and a cardiac CT scan for CAC at baseline (2000-2002). Among these, 2427 women had up to 3 follow-up cardiac CT scans at subsequent visits spanning 10 years. CAC was assessed by Agatson units. CAC and sex hormones were log-transformed for analysis. Using multivariable-adjusted Poisson and linear mixed effects models, we tested the longitudinal associations of testosterone (T), free T, dehydroepiandrosterone (DHEA), estradiol (E2), and sex hormone binding globulin (SHBG) with prevalent CAC and progression of CAC over 10 years. Results: At baseline, average age was 65 years, 46% had prevalent CAC and 32% were using hormone therapy (HT). Cross-sectionally, there were no associations between sex hormones and prevalent CAC. After adjustment for demographics, lifestyle factors and use of HT, higher levels of free T and lower levels of SHBG were associated with an increase in CAC progression over 10 years ( Table, Model 2). These associations remained statistically significant after adjusting for potential mediating cardiovascular risk factors (Model 3) and in sensitivity analyses excluding women on HT. Conclusion: A more androgenic hormone profile of higher free T and lower SHBG is associated with a greater CAC progression over 10 years in post-menopausal women. Sex hormone levels may help identify women at increased CVD risk who may benefit from other risk reduction strategies.
Conditioning on Parity in Studies of Perfluoroalkyl Acids and Time to Pregnancy: An Example from the Danish National Birth Cohort
Authors: Cathrine Carlsen Bach, Niels Bjerregård Matthiesen, Jørn Olsen, Tine Brink Henriksen
Journal: Environmental Health Perspectives (2018)

Background: Previous studies have investigated the associations between perfluoroalkyl acids (PFAAs) in women and time to pregnancy (TTP). Inconsistent results may be explained by differences in conditioning on parity. Objectives: We used causal directed acyclic graphs to illustrate potential confounding related to previous pregnancies and exposure measurement error due to differences in the interpregnancy interval in pregnancy-based studies that include parous women. We exemplified the potential importance of these issues using data from the Danish National Birth Cohort. Methods: We used discrete time survival models to estimate associations between maternal plasma PFAAs in early pregnancy and TTP in 638 nulliparous and 613 parous women. Results: PFAA quartiles were not associated with the TTP in nulliparous women. In parous women, higher PFAA quartiles were associated with longer TTP. The strongest associations were estimated for perfluorohexane sulfonate and perfluorooctane sulfonate. PFAA concentrations were higher in women with longer interpregnancy intervals. Accounting for the interpregnancy interval attenuated the estimated associations. Conclusions: Associations between PFAAs and TTP in parous women may be biased by confounders related to previous pregnancies and exposure measurement error. To avoid these biases, studies that include parous women may need to condition on a) common causes of PFAAs and the TTP in the index pregnancy, b) previous births (a descendant of a collider), c) PFAA levels or common causes of PFAA levels and the TTP in the previous pregnancy (to alleviate collider stratification bias caused by conditioning on previous births), and d) the interpregnancy interval (in pregnancy-based studies). Alternatives would be to restrict studies to nulliparous women or to use toxicokinetic modeling to correct exposure estimates in parous women. These recommendations may be extended to studies of other chemicals with similar toxicokinetic properties. https://doi.org/10.1289/EHP1493
Abstract MP13: Perceived Environmental Supports and Barriers are Associated with Physical Activity Behaviors During Pregnancy
Authors: Julie K Bower, Claire E Bollinger, Randi E Foraker, Darryl B Hood
Journal: Circulation (2016)

Background: In the absence of contraindications, current guidelines recommend ≥ 150 minutes/week of moderate-intensity aerobic activity for women during pregnancy for the prevention of excess weight gain, metabolic abnormalities (e.g., gestational diabetes), and the general health of both mother and offspring. In the U.S., approximately 20% of pregnant women meet this recommendation. The perceived quality of the built environment may play an important role in supporting or hindering active living during pregnancy. Thus, this study examined the association of environmental supports for physical activity (PA) with PA behaviors in a population of pregnant women. Methods: The study included 155 pregnant women in the Ohio State University Wexner Medical Center that self-reported PA behaviors during the third trimester (27+ weeks). Participants also rated 26 perceived environmental supports and barriers for PA in four domains: outdoor recreation supports, access to a safe walking environment, neighborhood and community supports, and public recreation facilities; the total environmental quality score ranged from 0 (worst) to 26 (best). Logistic regression was used to examine the association of the total and subscale scores with achievement of ≥150 minutes of moderate-to-vigorous physical activity (MVPA) during the pregnancy, maintenance of pre-pregnancy PA level, and change in moderate PA from the 1st through 3rd trimester. Results: The study included women between the ages of 20-46 years that were between 27-40 weeks pregnant. The mean age was 32 years (SD=4.3 years). Fifty percent of the study population reported achieving ≥150 minutes per week of MVPA. Women with access to a safe walking environment were more likely to maintain or increase their PA during pregnancy [adjusted OR (aOR) per 1-point increase in PA score = 1.61, 95% CI: 1.14-2.28, p&lt;0.01]; a safe walking environment was characterized by perceptions of physically active neighbors, lack of concern about unattended pets, safe and well-maintained sidewalks, and adequate street lighting. Participants that reported better access to public recreational facilities were also more likely to maintain or increase moderate PA levels throughout their pregnancy (aOR = 1.24, 95% CI: 1.05 - 1.47, p&lt;0.05). Conclusions: Perceived access to a safe environment and neighborhood public recreation facilities are strongly associated with achievement and maintenance of recommended PA throughout pregnancy. Interventions at the individual-level have been shown to promote PA during pregnancy. Combining these efforts with community-level interventions that enhance the built environment to include access to safe outdoor space for leisure and recreational facilities may also positively impact the metabolic health of expectant mothers.